Evidence map›Paper›PMID 40790864›Full record

ArticleThe American journal of case reports2025

Treatment of Multiple Recalcitrant Warts in an Immunocompromised Patient Using Purified Protein Derivative (PPD) Injection: A Case Report.

Fares A Alkhayal, Loujain A Alyousef

Abstract readCase Reports
In one paragraph

Article in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Fares A AlkhayalDermatology and Dermatologic Surgery Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Loujain A AlyousefDermatology Department, Security Forces Hospital, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Warts are common cutaneous viral infections primarily caused by human papillomavirus (HPV). They occur in all age groups, with immunocompromised individuals being particularly susceptible. Patients with compromised immune systems, such as those with acquired immunodeficiency syndrome (AIDS), organ transplant recipients, and individuals on immunosuppressive therapies, are at a higher risk of developing warts. These patients are also more likely to have severe and persistent warts, often necessitating multiple treatment approaches. Conventional therapies such as cryotherapy, laser ablation, and topical treatments often yield suboptimal results in this population due to their compromised immune response. Although intralesional immunotherapy, such as purified protein derivative (PPD), has been shown to stimulate a systemic immune response and facilitate wart clearance, its use in immunosuppressed individuals remains under-reported and under-utilized in clinical practice. CASE REPORT We report the case of a 70-year-old woman with a history of immunosuppression who presented with multiple recalcitrant warts on her left hand. Due to the persistence of lesions despite previous treatments, she received PPD injection sessions in a single lesion. Remarkably, all of her warts regressed completely within 6 weeks, with no recurrence observed during follow-up. No adverse effects were reported, highlighting the safety of this approach. CONCLUSIONS This case underscores the potential of PPD immunotherapy as an effective, safe, and well-tolerated treatment modality for warts in immunocompromised patients. Given its immunostimulatory properties and ability to induce systemic clearance, PPD should be considered a valuable alternative for managing refractory warts in this high-risk population. Further studies are warranted to establish standardized protocols and optimize its clinical application.

Indexed as

Immunocompromised HostWartsAgedFemaleHumans

Identifiers

PMID40790864
PMCPMC12357518

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.